Corporate strategies adopted by Indian Pharmaceutical Industry for restructuring
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 4
Abstract
The Indian pharmaceutical industry has developed rapidly over the last few decades. Before TRIPS, the Indian regulatory system recognized only process patents. The Indian Pharmaceutical companies were engaged in the development of new processes for manufacturing drugs. They mainly concentrated on the domestic markets and unregulated markets. The Indian companies focused very little on Research & Development (R&D). Even large pharmaceutical companies showed little interest on innovation and R & D. They mostly depended on imitation and reverse engineering of the patented products. But after TRIPS, product patent was reintroduced and the companies spent their expenditure on R&D, synthesis of new chemical entities (NEC), and on modification of already existing entities to develop new formulations and development of generics to obtain regulatory approvals for marketing already patent expired drugs. The multinational companies have turned to contract manufacturing and research services (CRAMS), marketing alliances, collaborative research and clinical trials to save time and cost. The main advantage of the Indian firms lies with their capability for low cost of production, and in their highly skilled technical labour. The manufacturing cost is less in India when compared to the US and the European countries. The Indian Pharmaceutical industry developed different types of strategies in order to survive and expand in the international pharmaceutical sector which involve collaborative strategies, business strategies, and overall corporate growth strategies.
Authors and Affiliations
Bhuvana Madhuri Chokkakula, Venkata Ramana Murthy Kolapalli, Vijaya Ratna Jayanti
Keywords
Related Articles
- EP ID EP427000
- DOI 10.22270/ijdra.v6i4.282
- Views 103
- Downloads 0
MARKETING AUTHORIZATION APPLICATION (MAA) FOR EUROPE MARKET
This article states requirement of Marketing Authorization Application to get registration of Drug Product to EEA. The procedures for application of marketing authorization are: Centralised procedure, National procedure,...
Covering Global Pharmaceutical Regulations in a Quality System
This article describes how to address compliance with a wide range of applicable regulations within a company’s quality system. The focus is on the way regulatory intelligence can be obtained and subsequently be interpre...
Integrating PLCM strategy in Pharmaceutical Emerging Market
All products and services must denote definite life cycles. The life cycle talks about the period from the product‘s first launch till it wind-up onto the market. Throughout this age noteworthy modifications are made in...
Nanoparticles and target Drug delivery for cancer treatment: A Comprehensive review
In the healthcare industry, the biggest challenges are cancer. However, there are several drugs are available for the treatment of cancer. In these treatments cure cancer affecting the collateral toxicity to healthy cell...
Regulatory requirements for Dossier submission in African Countries (Kenya, Uganda, and Tanzania) - A Review
Africa is world’s second fastest growing pharmaceutical market. The CGAR of African Pharmaceutical market is 10.6%. African people suffer from numerous diseases. The local pharmaceutical market is weak and insufficient t...